Darren M. Black, who serves as a director at LifeStance Health Group, Inc. (NASDAQ: LFST), has disclosed the indirect sale of 5,899,661 shares of common stock on May 12, 2026. The transaction resulted in proceeds totaling approximately $47,315,281, based on a selling price of $8.02 per share.
This reported sale took place amid recent market volatility for the company's stock. At the time of the transaction, LFST was trading at $7.89, which represented a decline from the previous closing price of $8.10. This movement reflected a challenging week during which shares had dropped nearly 11%.
Details of the Transaction
The disposition of the shares was structured indirectly through several Summit Partners funds and advisory vehicles. Specific sales included:
- 3,612,708 shares sold by Summit Partners Growth Equity Fund IX-A, L.P.
- 2,255,726 shares sold by Summit Partners Growth Equity Fund IX-B, L.P.
- 25,218 shares sold by Summit Investors GE IX/VC IV, LLC.
- 3,371 shares sold by Summit Partners Entrepreneur Advisors Fund II, L.P.
- 2,638 shares sold by Summit Investors GE IX/VC IV (UK), L.P.
Following these sales, the entities beneficially associated with Mr. Black maintain a total indirect beneficial ownership of 23,310,115 shares of LifeStance Health common stock. These holdings are distributed across various funds and entities:
- Summit Partners Growth Equity Fund IX-A, L.P.: 14,274,150 shares
- Summit Partners Growth Equity Fund IX-B, L.P.: 8,912,582 shares
- Summit Investors GE IX/VC IV, LLC: 99,639 shares
- Summit Partners Entrepreneur Advisors Fund II, L.P.: 13,320 shares
- Summit Investors GE IX/VC IV (UK), L.P.: 10,424 shares
Despite the recent dip in stock value over the past week, the overall performance metrics for LFST remain strong when viewed longer-term. The stock has generated returns of 23% over a six-month period and an even higher return of 37% across the preceding year.
Corporate Financial Developments
In separate corporate news, LifeStance Health Group reported robust financial outcomes for its first quarter of 2026. The company significantly outperformed market expectations in terms of profitability and revenue generation. Specifically, the earnings per share (EPS) reached $0.04, a marked improvement compared to the forecasted $0.01. Furthermore, quarterly revenue totaled $403.48 million, surpassing the anticipated figure of $387.43 million.
Beyond these strong financial reports, LifeStance Health Group also conducted an underwritten public offering involving 35 million shares sold by existing stockholders. These shares were priced at $8.15 per share. It is critical to note that all proceeds from this specific transaction went directly to the selling stockholders; consequently, LifeStance did not issue any new stock and received no proceeds.
The process was managed with J.P. Morgan Securities LLC serving as the underwriter for the offering. Additionally, the company has announced plans to repurchase 6 million shares from the selling stockholders at the same price point established during the public offering.
Structural Context and Analysis
Mr. Black's beneficial ownership stake originates from his capacity as a Managing Director and Member of Summit Master Company, LLC. This entity holds control over the general partners and managers associated with the listed Summit Partners entities. The broader firm, Summit Partners, L.P., further solidifies its involvement through an investment committee that includes Mr. Black. Through these various holdings, the reporting parties and individuals explicitly disclaim any beneficial ownership rights except to the extent of their documented pecuniary interest.
While recent insider selling occurred against a backdrop of market weakness for LFST, other data points suggest underlying strength. An InvestingPro analysis suggests that the stock may remain undervalued at its current trading levels, adding 13 additional ProTips for subscribers seeking further insight into potential valuation gaps.